| Ticker Details |
REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
|
| IPO Date: |
September 17, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$809.07M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.80 | 3.18%
|
| Avg Daily Range (30 D): |
$0.40 | 4.61%
|
| Avg Daily Range (90 D): |
$0.40 | 4.51%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.42M |
| Avg Daily Volume (30 D): |
2.02M |
| Avg Daily Volume (90 D): |
1.35M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
85 |
| Avg Trade Size (Sh.) (90 D): |
82 |
| Institutional Trades |
| Total Institutional Trades: |
3,495 |
| Avg Institutional Trade: |
$1.9M |
| Avg Institutional Trade (30 D): |
$1.62M |
| Avg Institutional Trade (90 D): |
$1.32M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.13M |
| Avg Closing Trade (30 D): |
$2.14M |
| Avg Closing Trade (90 D): |
$1.39M |
| Avg Closing Volume: |
85.3K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-5.6
|
$-1.72
|
$-1.3
|
|
Diluted EPS
|
$-5.6
|
$-1.72
|
$-1.3
|
|
Revenue
|
$87.82M
|
$6.39M
|
$30.34M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-290.01M
|
$-90.05M
|
$-67.15M
|
|
Operating Income / Loss
|
$-256.69M
|
$-83.36M
|
$-57.64M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-114.88M
|
$-19.24M
|
$-24.34M
|
|
PE Ratio
|
|
|
|
|
|
|
